Interpreting the STAR*D Trial
The Carlat Psychiatry Report, Volume 4, Number 5, May 2006
https://www.thecarlatreport.com/newsletter-issue/tcprv4n5/
Issue Links: Learning Objectives | Editorial Information
Topics: Antidepressants
John Rush, MD
Professor of Psychiatry, University of Texas Southwestern Medical School
Principal Investigator and Study Director, STAR*D Trial
Dr. Rush has disclosed that he was or is a consultant for Bristol Myers Squibb, Cyberonics, GlaxoSmithKline, Neuronetics, Ono, Organon; was or is a member of the speakers bureau of Cyberonics, Forest and GlaxoSmithKline; and was or is a stock shareholder of Pfizer Pharmaceuticals. The editors of The Carlat Psychiatry Report have closely reviewed the content of Dr. Rush’s interview and have determined that there are no financial conflicts of interest regarding this educational activity.
Dr. Rush, thanks for agreeing to help us understand the STAR*D trial. You were the overall principal investigator of what I believe was the largest study in history comparing different antidepressants. Looking at the first set of results, are you encouraged by the findings?
You can't view details of this content, please login or buy subscription here